MLAB falls within the Life Sciences Tools & Services industry. Net loss totals approximately $1.97 million, with gross profit of about $154.48 million. The company maintains approximately $43.75 million in cash.
Mesa Laboratories (MLAB) currently is priced at $104.65 as of May 10, 2026, representing a 1.39% decrease on the day after opening at $106.12 with an intraday range between $98.09 and $105.92. Mesa Laboratories currently exhibits 29% estimated likelihood of financial distress over the forecast period. Over the prior 90 trading days, Mesa Laboratories has produced modest risk-adjusted performance, in line with its contained performance profile. The performance scores are measured across the period from February 9, 2026 to May 10, 2026. Learn more.
Mesa Laboratories (MLAB) is listed on NASDAQ Exchange in USA. Mesa Laboratories operates within the Life Sciences Tools & Services segment. Mesa Laboratories market capitalization is $586.29 million, placing the company in the small-cap tier across life sciences tools & services. Supporting market cap data includes about 5.52 million shares outstanding, enterprise value near $737.39 million, and a workforce of about 730 people. Mesa Laboratories has 198,395 shares sold short (1.84 days to cover). The gap between operating margin (12.25%) and net margin (1.51%) suggests significant non-operating costs such as interest or taxes. The elevated P/E of 433.94 combined with ROE of 2.18% may reflect growth expectations beyond current return levels. Mesa Laboratories is a professional services provider where revenue is driven by client demand, contract value, and utilization rates. MLAB has return on total asset (ROA) of 2.47% a positive efficiency signal. This is lower than average in the industry. Mesa Laboratories also reports a return on stockholder's equity (ROE) of 2.18%, indicating positive capital compounding. Mesa Laboratories financial stability analysisOwnership Allocation The majority of Mesa Laboratories' outstanding shares are owned by institutional holders. Institutional investors such as pension funds, mutual funds, and asset managers typically hold large positions as part of their investment mandates, managing money on behalf of clients or beneficiaries. As a result, they are subject to reporting requirements and oversight rules - such as 13F filings and position disclosure thresholds - that do not apply to individual retail investors.
Check Mesa Ownership DetailsESG Sustainability
Latest disclosures for Mesa Laboratories show an ESG Environmental Score of 64.52, an ESG Governance Score of 68.50, and an ESG Social Score of 64.89. Mesa Laboratories demonstrates above-median ESG positioning within Life Sciences Tools & Services. ESG metrics are often used to evaluate governance structure, sustainability exposure, and risk oversight. Recent disclosures may influence how governance practices are evaluated.
Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite Total, Nasdaq Industrial, Health Care, Life Sciences Tools & Services, Scientific & Technical Instruments, Technology, (View all Sectors)
Common Risk Profiles
Investors typically prefer the highest possible return while minimizing volatility. Mesa Laboratories market risk premium represents the extra return above the risk-free rate for holding Mesa Laboratories.
Mesa Laboratories develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado. Mesa Laboratories employs 730 people. Headquarters are in 12100 West Sixth Avenue, Lakewood, CO, United States, 80228. Key reported metrics include market cap 586.29 million, P/E 433.94. Mesa Laboratories operates in Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Reported fundamentals are aligned with observed market behavior. Lower trading activity may introduce occasional variability in execution conditions.
Methodology
Unless otherwise specified, financial data for Mesa Laboratories is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Mesa (USA Stocks:MLAB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR. Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Mesa Laboratories may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board
Mesa Laboratories Corporate Executives
Board and executive analysis for Mesa Laboratories is useful because governance quality can influence capital allocation, accountability, and long-term strategic consistency. Institutions hold about 94.37% of shares while insiders own roughly 5.43%.
A broader look at Mesa Laboratories comes from its financial reports and historical data. Highlighted below are reports that provide context for Mesa Laboratories Stock: